Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader

EVO301 late-breaking EADV data demonstrate clear therapeutic signal and favorable safety and tolerability profile, supporting Phase 2b trial in AD expected for mid-2027 initiation

Additional clinical milestones expected in 2027, including initiation of the EVO570 Phase 1 trial in early 2027, the EVO301 Phase 2 trial in ulcerative colitis and the EVO646 Phase 1 study

Key 2027 data expected to include Phase 1 healthy volunteer and biomarker data for EVO570 and EVO646, and top-line Phase 2b migraine data for EVO756

Strong balance sheet with cash runway into 2H 2029 to deliver multiple key milestones across the pipeline

PALO ALTO, Calif. & NEW YORK, November 12, 2026 - Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved,” said Luis Peña, President and Chief Executive Officer at Evommune. “As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”

Recent Business Highlights and Upcoming Milestones

EVO301 – Injectable IL-18 Binding Protein Fusion Protein

Anti-serum albumin Fab-associated (SAFA) IL-18BP fusion protein designed to neutralize IL-18 activity, which is aberrantly upregulated in many inflammatory and autoimmune diseases. Targeting IL-18 offers a novel upstream approach that extends beyond Th2 to address multiple inflammatory pathways, with the potential to serve a broad range of patients.

EVO756 – Oral MRGPRX2 Antagonist for Migraine Prophylaxis

Potent and highly selective small-molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor found predominantly on peripheral sensory neurons and mast cells.

EVO570 – Oral VAV-1 Molecular Glue Degrader

Oral, highly selective VAV-1 molecular glue degrader (MGD) designed to deliver JAK-like efficacy in autoimmune disease. VAV-1 is a signaling protein, largely restricted to immune cells, that drives T- and B-cell activation across a wide range of chronic inflammatory diseases.

EVO646 – Oral TLR7/8 Antagonist

Selective oral TLR7/8 antagonist with the potential to offer a more targeted approach to controlling upstream drivers of lupus and other interferon-, myeloid inflammation- and autoantibody-driven conditions.

Corporate Updates

Third Quarter 2026 Financial Results

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that result from the limitations of existing therapies. For more information, please visit www.evommune.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of the Company’s product candidates; the design, objectives, initiation, timing, progress and results of the Company’s clinical trials, including the planned Phase 2b trial of EVO301 in AD, the planned Phase 2 trial of EVO301 in ulcerative colitis, the ongoing Phase 2b trial of EVO756 in migraine, the planned Phase 1 trials of EVO570 and EVO646 and the planned Phase 2 program for EVO570 in rheumatoid arthritis; the potential benefits of the Company’s license agreement with Hinova Pharmaceuticals and royalty and other payment obligations under the license agreement; anticipated cash runway into the second half of 2029; the intended use of proceeds from the private placement; estimates of patient populations and market opportunities; the Company’s ability to achieve development and corporate milestones and create value for patients and stockholders; and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, as supplemented by the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Media and Investors:

Megan Humphreys

megan.humphreys@evommune.com